Lung Cancer

“Just as radiation therapy and chemotherapy identified a new way to treat cancer in the 20th century, Qu Biologics’ SSIs are identifying a new way for the 21st century.”

 ~ Dr. Simon Sutcliffe, Chief Medical Officer, Qu Biologics

Qu Biologics’ QBKPN SSI, derived from components of inactivated K. pneumoniae, is designed to stimulate an innate immune response in the lungs and reverse the immune dysfunction that underlies cancer development and progression. Qu has completed a Health Canada-approved clinical trial at the BC Cancer Agency Research Centre to evaluate immunological response to SSI treatment in patients with recurrent lung cancer. A summary of the key results has been published in OncoImmunology.

Restoring immune function to treat lung cancer

Unlike current treatments that target the cancer cells, Qu’s SSIs are designed to activate the patient’s own immune cells, restoring normal immune function. Treatment with lung targeted QBKPN SSI, derived from components of inactivated K. pneumoniae (a common lung pathogen), recruits activated innate immune cells to the lungs, re-establishing the body’s capacity to mount an effective anti-cancer immune response. Read more about How SSIs Work.

Lungs

Qu Biologics’ lung cancer clinical trial

Qu Biologics has completed a Health Canada-approved Phase 1/2 exploratory clinical trial to evaluate the mechanism of action and the safety, tolerability and compliance of QBKPN SSI treatment in patients with recurrent non-small cell lung cancer. The study took place at the B.C. Cancer Agency, in Vancouver, B.C., and was led by Principal Investigator Dr. Stephen Lam, a leading Canadian lung cancer detection and prevention clinical researcher. In addition to assessing safety, the trial was designed to look at the immunological effects of SSI treatment over a 12-week period.

As published in OncoImmunology, results indicated that QBKPN treatment was well tolerated and induced anti-cancer immunological changes. Further, computed tomography (CT) scans were stable over the 12-week period of QBKPN administration. Importantly, QBKPN treatment was found to reduce expression of both PD-1 and PD-L1, two molecules that inhibit immune cells from attacking cancer. Immunological studies suggested that further studies of peripheral blood M1:M2 ratios and PD-1 and PD-L1 expression in patients with lung cancer may provide insights into the mechanism of action of SSIs and justify further clinical study.

Past events:


Past events: